StockWatch
·
Pharmaceuticals
Quarterly Result28 May 2026, 11:09 pm

Parnax Lab Approves Q4/FY26 Results; Re-appoints Independent Director

AI Summary

Parnax Lab Limited's Board of Directors approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. Concurrently, the Board, based on the Nomination & Remuneration Committee's recommendation, approved the re-appointment of Mr. Yogesh K. Varia as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 28, 2026, to May 27, 2031. This re-appointment is subject to approval by members at the upcoming General Meeting. The company confirmed that Mr. Varia is not debarred from holding a directorship by any regulatory authority. The auditors expressed an unmodified opinion on the standalone audited financial results.

Key Highlights

  • Board approved Q4 and FY26 standalone & consolidated audited financial results.
  • Mr. Yogesh K. Varia re-appointed as Independent Director for a second 5-year term.
  • Re-appointment is from May 28, 2026, to May 27, 2031, subject to shareholder approval.
  • Auditors issued an unmodified opinion on the standalone audited financial results.
  • Mr. Varia has over 40 years of experience in pharmaceutical and cosmetics manufacturing.